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Dear Editor:
It is mandatory to find antiretroviral thera-
pies that offer increased efficacy in treatment-
experienced patients with HIV-1 infection, a
population whose extensive drug resistance re-
stricts treatment options and has a severe effect
on infection management.1 The aim in salvage
therapy in patients who were highly treatment-
experienced and in whom multiple regimens
had failed was so far limited to the new pro-
tease inhibitors (PI) and combination with en-
fuvirtide.2,3
The new antiretrovirals currently in ex-
panded access programs, such as raltegravir
and etravirine, show unprecedented level of vi-
rologic efficacy. Raltegravir, formerly MK-
0518, the first integrase inhibitor under clinical
development, showed high potency in mul-
tidrug-resistant HIV patients including those
resistant to currently available antiretroviral
drugs.4 Etravirine, formerly TMC-125, a sec-
ond-generation non-nucleoside reverse tran-
scriptase inhibitor (NNRTI) appears to be ef-
fective against a variety of HIV viruses that are
resistant to efavirenz and nevirapine.5
Few data are available regarding the perfor-
mance of these drugs combinations in heavily
PI-experienced patients, including those for
whom tipranavir, darunavir, and enfuvirtide
have failed. Hereby, we describe the outcome
of salvage therapy based on raltegravir and
etravirine in a heavily antiretroviral-experi-
enced patient. A 37-year-old Caucasian male,
CDC status C3, had experienced multiple fail-
ures to all current classes of antiretroviral
agents. Specifically, he had failed eight riton-
avir-boosted PI combinations, including teno-
fovir-lamivudine-enfuvirtide-tipranavir/riton-
avir, given in May 2004 with replacement of the
latest with darunavir/ritonavir in December
2006.
Plasma HIV-RNA levels were measured at
baseline and during therapy using a commer-
cial assay, the Versant HIV-1 RNA 3.0 Assay
(bDNA; Siemens Medical Solutions Diagnos-
tics, Malvern, PA), with a dynamic range of
50–500,000 HIV-1 RNA copies per milliliter.
CD4 cell count was determined by direct im-
munofluorescence in flow cytometry (Beckman
Coulter, Fullerton, CA).
Genetic analysis of the pol gene including
both HIV-1 reverse transcriptase (codons 4-99)
and protease (codons 35-247) regions was per-
formed using the Trugene HIV-1 Genotyping
Kit (Siemens Medical Solutions Diagnostics).
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Genetic analysis of the env gene was performed
amplifying and sequencing a gp41 fragment
that included HR1 and HR2 regions using
primers supplied by Siemens Medical Solu-
tions Diagnostics. Drug resistance mutations
within the pol and env genes were examined
following the latest International AIDS Soci-
ety—USA panel list published in 2007.6 In
April 2007 the patient’s plasma HIV-RNA level
was more than 5.7 log10 copies per milliliter and
the CD4 cell count was 18 cells per microliter.
The genotype revealed the presence of L10I,
K20R, V32I, L33F, M36I, I47V, G48V, I50V,
I54L/M, L63P, A71V, G73S, V82T, I84V muta-
tions within protease; and M41L, D67N, V75T,
T69D, A98G, K101A, V118C, Y181C, G190A,
M184V, L210W, T215F mutations within tran-
scriptase.
In summary there were multiple drug resis-
tance mutations, which conferred high-level
resistance to most currently available anti-
retroviral agents, included tipranavir and
darunavir, and the mutation V38A to enfuvir-
tide in the HR1 region of the gp41.
Given the dramatic clinical and virological 
situation, a new regimen including emtricitabine/
tenofovir fixed dose, darunavir/ritonavir, ralte-
gravir 600 mg twice per day and etravirine 200
mg twice per day was started. The patient had a
significant decline in plasma HIV RNA to 2.4
log10, and an increase in the CD4 cell count to
194 cells per microliter (8%), within 24 weeks of
therapy (Fig. 1). Recent reports have highlighted
the fact that mutations V32I, L33F, I47V, I50V
I54L/M and G73S, are associated with lower sus-
ceptibility to darunavir and selected in patients
failing this drug.7
In regard to entry inhibitors, it is known that
gp41 single-point mutation between positions
36-45 reduces enfuvirtide susceptibility from
10- to 20-fold. Our patient exhibited only the
V38A mutation in the HR1 region. This amino
acid change is known to sustain an immuno-
logic response.8 Unfortunately, this finding
was not present in our patient who presented
CD4 cell count 50 cells per L all along en-
fuvirtide treatment. And enfuvirtide was not
included in the last regimen due to very painful
injections, after a longer than 2-year treatment
period.
Few data are available on raltegravir: a re-
cent study shows a rapid, and sustained anti-
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FIG. 1. Virologic and immunologic outcome: from April 2007 the patient started new regimen including emtric-
itabine/tenofovir fixed dose, darunavir/ritonavir, raltegravir and etravirine. , start of the new regimen; , CD4 cell
count (cells/mm3); , viral load [plasma HIV-RNA (log)].
retroviral effect in patients who had triple class
resistant virus, and a limited number of active
antiretrovirals in their background regimen.4
Etravirine has antiviral activity in patients
with NNRTI resistance, but three or more mu-
tations were associated with decreased viro-
logic response.5 In our patient, the presence of
three mutations (A98G, Y181C, and G190A),
had not compromised the efficacy.
The tolerability was good and no serious ad-
verse events were recorded. No signs of clini-
cal progression were seen during the first 24
weeks of therapy. These results highlight the
strong antiviral activity and good safety of ral-
tegravir and etravirine in deep salvage in heav-
ily antiretroviral-experienced patients, includ-
ing individuals who had failed tipranavir,
darunavir, and enfuvirtide.
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